RenalSense

RenalSense is a biotechnology startup hailing from Israel, founded in 2009. The company's slogan, "Realtime Renal Diagnostics," perfectly encapsulates its mission to revolutionize renal diagnostics. RenalSense's flagship product, Clarity RMS, is a groundbreaking medical device that offers continuous monitoring of urine flow for real-time assessment of renal function and early detection and prevention of ICU-acquired Acute Kidney Injury (AKI). In the current medical landscape, over 30% of critical care patients develop AKI, resulting in significant additional hospital costs and high mortality rates reaching up to 83% for patients requiring dialysis. Renal function assessment in ICUs typically relies on manual and intermittent urine volume measurements, leading to subjective evaluations. This outdated approach results in delayed responses and can contribute to worsening patient outcomes. Clarity RMS represents a paradigm shift in this respect. It consists of an electronic sensor that seamlessly connects to a Foley catheter, enabling continuous and reliable measurement of urine flow. This data is automatically collected and transmitted, reducing human error and providing crucial real-time information, displayed graphically on a bedside monitor. In this context, the recent $14.00M Series A investment from BlueRed Partners at 22 November 2021 underscores the growing confidence in RenalSense's innovative approach. This injection of capital not only validates the potential of RenalSense but also highlights the crucial importance of advancements in medical technology, particularly in the context of critical care. With the backing of BlueRed Partners, RenalSense is poised to further develop and commercialize Clarity RMS, potentially reshaping renal diagnostics and positively impacting patient care in ICUs worldwide.